Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-5366 in Healthy Subjects and Subjects With Recurrent Genital Herpes
NCT06385327Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- May 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ABI-5366 in genital herpes and herpes simplex virus type 2 infection (5 arms), sponsored by Assembly Biosciences, Inc. Primary endpoints: Area Under the Plasma Concentration Time Curve up to 8 hours, Maximum Observed Plasma Concentration up to 8 hours and 6 more. Started May 2024; status: completed.
02
Drugs
ABI-5366
03
Conditions
genital herpesherpes simplex virus type 2 infection
Beyond the preview
Go deeper on NCT06385327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385327.